Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.45 |
| ▸ | RHEB | Q15382 | 2/20 | 0.41 |
| ▸ | EPAS1 | Q99814 | 8/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.39 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.39 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.39 |
| ▸ | VEGFA | P15692 | 4/20 | 0.38 |
| ▸ | DHPS | P49366 | 1/20 | 0.37 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29337679 | 0.89 | BRD4 (0.44) | BRD4RHEBEPAS1AREGFR | |
| SCHEMBL30217170 | 0.89 | BRD4 (0.44) | BRD4RHEBEPAS1AREGFR | |
| SCHEMBL30967840 | 0.82 | PRKCQ (0.47) | BRD4RHEBEPAS1AREGFR | |
| SCHEMBL27275421 | 0.82 | PRKCQ (0.47) | BRD4RHEBEPAS1AREGFR | |
| SCHEMBL30967802 | 0.80 | EPAS1 (0.49) | BRD4RHEBEPAS1AREGFR | |
| SCHEMBL29237661 | 0.80 | EPAS1 (0.49) | BRD4RHEBEPAS1AREGFR | |
| SCHEMBL27275422 | 0.80 | EPAS1 (0.49) | BRD4RHEBEPAS1AREGFR | |
| SCHEMBL30967931 | 0.79 | BRD4 (0.46) | BRD4RHEBEPAS1AREGFR | |
| SCHEMBL29237251 | 0.79 | BRD4 (0.46) | BRD4RHEBEPAS1AREGFR | |
| SCHEMBL29337971 | 0.79 | BRD4 (0.46) | BRD4RHEBEPAS1AREGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | GENZYME CORPORATION | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239784-A1 | INDOLE COMPOUNDS AND METHODS OF USE | CFTR, INMT, IDO1 | BRD4 651/4885RHEB 3259/4885EPAS1 2305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.